Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCGR | P47871 | 2/20 | 0.44 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.42 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.40 |
| ▸ | MEN1 | O00255 | 3/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 3/20 | 0.38 |
| ▸ | RAB9A | P51151 | 3/20 | 0.38 |
| ▸ | GBA1 | P04062 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | GRM5 | P41594 | 1/20 | 0.38 |
| ▸ | CASP3 | P42574 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6501885 | 0.88 | GCGR (0.44) | GCGRHDAC7L3MBTL1KMT2ACYP3A4 | |
| SCHEMBL6499114 | 0.85 | HDAC7 (0.47) | GCGRHDAC7L3MBTL1KMT2ACYP3A4 | |
| SCHEMBL6645478 | 0.85 | SORT1 (0.42) | SORT1KMT2ACYP3A4MEN1CYP1A2 | |
| SCHEMBL6489227 | 0.83 | CTNNB1 (0.48) | GCGRHDAC7L3MBTL1KMT2ACYP3A4 | |
| SCHEMBL6498923 | 0.83 | APOB (0.43) | GCGRSORT1 | |
| SCHEMBL6498569 | 0.82 | ALOX15 (0.44) | GCGRSORT1HDAC7L3MBTL1KMT2A | |
| SCHEMBL6503526 | 0.81 | TRPV1 (0.43) | GCGRTP53 | |
| SCHEMBL6498069 | 0.81 | HDAC7 (0.49) | GCGRHDAC7L3MBTL1KMT2ACYP3A4 | |
| SCHEMBL6501037 | 0.81 | GCGR (0.41) | GCGRSORT1HDAC7L3MBTL1KMT2A | |
| SCHEMBL6500853 | 0.81 | CHRNB2 (0.42) | GCGRSORT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040048911-A1 | 1-phenyl imidazol-2-one biphenylmethyl compounds for treatment of circulatory disorders | G. D. SEARLE & CO. | 2004-03-11 | — | — | US | claimed |
| US-20020038035-A1 | 1-phenyl imidazol-2-one biphenylmethyl compounds for treatment of circulatory disorders | G.D. SEARLE & CO. | 2002-03-28 | — | — | US | claimed |
| EP-0690854-B1 | 1-PHENYL-IMIDAZOL-2-ONE BIPHENYLMETHYL COMPOUNDS FOR TREATMENT OF CIRCULATORY DISORDERS | SEARLE & CO (US) | 2000-07-12 | — | — | EP | claimed |
| EP-0978515-A2 | 1-(substituted phenyl)-4-biphenylmethyl-imidazol-2-one derivatives, their preparation and their use as angiotensin II antagonists | G.D. SEARLE & CO. (US) | 2000-02-09 | — | — | EP | claimed |
| US-6858636-B2 | 1-phenyl imidazol-2-one biphenylmethyl compounds for treatment of circulatory disorders | G.D. SEARLE & CO. (US) | 2005-02-22 | — | — | US | disclosed |
| US-20050038035-A1 | Heterocyclic amide compounds as apolipoprotein b inhibitors | DAISO CO., LTD. (JP) | 2005-02-17 | — | — | US | disclosed |
| US-20040048911-A1 | 1-phenyl imidazol-2-one biphenylmethyl compounds for treatment of circulatory disorders | G. D. SEARLE & CO. | 2004-03-11 | — | — | US | disclosed |
| US-6630497-B2 | 1-phenyl imidazol-2-one biphenylmethyl compounds for treatment of circulatory disorders | G.D. SEARLE & CO | 2003-10-07 | — | — | US | disclosed |
| US-20020038035-A1 | 1-phenyl imidazol-2-one biphenylmethyl compounds for treatment of circulatory disorders | G.D. SEARLE & CO. | 2002-03-28 | — | — | US | disclosed |
| EP-0690854-B1 | 1-PHENYL-IMIDAZOL-2-ONE BIPHENYLMETHYL COMPOUNDS FOR TREATMENT OF CIRCULATORY DISORDERS | SEARLE & CO (US) | 2000-07-12 | — | — | EP | disclosed |
| EP-0978515-A2 | 1-(substituted phenyl)-4-biphenylmethyl-imidazol-2-one derivatives, their preparation and their use as angiotensin II antagonists | G.D. SEARLE & CO. (US) | 2000-02-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020038035-A1 | 1-phenyl imidazol-2-one biphenylmethyl compounds for treatment of circulatory disorders | AGTR1, AGTR2, REN | GCGR 648/4885SORT1 4699/4885HDAC7 1717/4885 |
| US-20040048911-A1 | 1-phenyl imidazol-2-one biphenylmethyl compounds for treatment of circulatory disorders | AGTR1, AGTR2, REN | GCGR 648/4885SORT1 4699/4885HDAC7 1717/4885 |
| US-20050038035-A1 | Heterocyclic amide compounds as apolipoprotein b inhibitors | APOB, APOL1, CTRB2 | GCGR 1784/4885SORT1 2352/4885HDAC7 876/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.